<DOC>
	<DOCNO>NCT00369018</DOCNO>
	<brief_summary>The study determine best drug ( MAL HAL ) dosage photodynamic therapy cervical precancerous lesion ( dysplasia ) woman refer conisation ( surgery ) .</brief_summary>
	<brief_title>A Dose-finding Study MAL HAL Photodynamic Therapy Cervical Premalignant Lesions .</brief_title>
	<detailed_description>Surgery ( conisation ) precancerous cervical lesion ( dysplasia ) increase risk preterm delivery young woman . Photodynamic therapy ( PDT ) selective , tissue preserve method may become good treatment option patient . This study explore topical application methyl aminolevulinate ( MAL ) hexaminolevulinate ( HAL ) cervix photodynamic therapy use red light ( 630 nm ) . Different dos MAL HAL use different application time , follow illumination .</detailed_description>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<mesh_term>Methyl 5-aminolevulinate</mesh_term>
	<criteria>Positive histology CIN 13 Patients endocervical lesion Patients AGUS Patients invasive disease Patients porphyria Patients sensitive MAL HAL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>photodynamic therapy</keyword>
	<keyword>methyl aminolevulinate</keyword>
	<keyword>hexaminolevulinate</keyword>
	<keyword>dose-finding</keyword>
	<keyword>cervical dysplasia</keyword>
</DOC>